Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
| ▸ | G6PD | P11413 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10328160 | 0.91 | NSD2 (0.49) | MAPK1KMT2AKDM4EMEN1HTT | |
| SCHEMBL10328161 | 0.88 | NSD2 (0.53) | MAPK1KMT2AKDM4EMEN1HTT | |
| SCHEMBL13404895 | 0.82 | MGLL (0.37) | MAPK1KMT2AKDM4EMEN1HTT | |
| SCHEMBL29354362 | 0.77 | MAPK1 (0.54) | MAPK1KMT2AMEN1HTTALDH1A1 | |
| SCHEMBL79589 | 0.77 | MAPK1 (0.54) | MAPK1KMT2AMEN1HTTALDH1A1 | |
| SCHEMBL29189790 | 0.76 | CA12 (0.61) | MAPK1KMT2AMEN1CA12CA1 | |
| SCHEMBL2575973 | 0.76 | CA12 (0.42) | MAPK1KMT2ACA12CA1CA9 | |
| SCHEMBL13404894 | 0.76 | CA12 (0.42) | MAPK1KMT2AKDM4ENSD2G6PD | |
| SCHEMBL4528176 | 0.76 | HSP90AA1 (0.55) | MAPK1KMT2AHTTCA12CA1 | |
| SCHEMBL22076666 | 0.74 | MGLL (0.33) | MAPK1KMT2AKDM4EMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120141416-A1 | MULTIMERIC PEPTIDE CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2012-06-07 | — | — | US | claimed |
| EP-2448965-A1 | MULTIMERIC PEPTIDE CONJUGATES AND USES THEREOF | Angiochem Inc. (CA) | 2012-05-09 | — | — | EP | claimed |
| WO-2011000095-A1 | MULTIMERIC PEPTIDE CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2011-01-06 | — | — | WO | claimed |
| US-20240199695-A1 | PEPTIDE COMPOUNDS AND PEPTIDE CONJUGATES FOR THE TREATMENT OF CANCER THROUGH RECEPTOR-MEDIATED CHEMOTHERAPY | TRANSFERT PLUS, S.E.C. (CA) | 2024-06-20 | — | — | US | disclosed |
| US-20240156971-A1 | METHODS AND SORTILIN BINDING CONJUGATE COMPOUNDS FOR TARGETING CANCER STEM CELLS | TRANSFERT PLUS, SOCIÉTÉ EN COMMANDITE (CA) | 2024-05-16 | — | — | US | disclosed |
| US-11780882-B2 | Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy | TRANSFERT PLUS, S.E.C. (CA) | 2023-10-10 | — | — | US | disclosed |
| US-20230036041-A1 | SORTILIN BINDING CONJUGATE COMPOUNDS, COMPOSITIONS AND USES THEREOF FOR TREATING CANCER | THERATECHNOLOGIES INC. (CA) | 2023-02-02 | — | — | US | disclosed |
| US-20220000971-A1 | METHODS AND COMPOUNDS FOR TARGETING SORTILIN RECEPTORS AND INHIBITING VASCULOGENIC MIMICRY | TRANSFERT PLUS, S.E.C. (CA) | 2022-01-06 | — | — | US | disclosed |
| EP-3925969-A1 | PEPTIDE COMPOUNDS AND PEPTIDE CONJUGATES FOR THE TREATMENT OF CANCER THROUGH RECEPTOR-MEDIATED CHEMOTHERAPY | Transfert Plus, S.E.C. (CA) | 2021-12-22 | — | — | EP | disclosed |
| US-11034727-B2 | Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy | TRANSFERT PLUS, S.E.C. (CA) | 2021-06-15 | — | — | US | disclosed |
| EP-3380495-B1 | PEPTIDE COMPOUNDS AND PEPTIDE CONJUGATES FOR THE TREATMENT OF CANCER THROUGH RECEPTOR-MEDIATED CHEMOTHERAPY | TRANSFERT PLUS SEC (CA) | 2021-05-19 | — | — | EP | disclosed |
| WO-2014026283-A1 | PEPTIDE-DENDRIMER CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2014-02-20 | — | — | WO | disclosed |
| US-20130280281-A1 | SHORT AND D-AMINO ACID-CONTAINING POLYPEPTIDES FOR THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2013-10-24 | — | — | US | disclosed |
| EP-2588490-A1 | SHORT AND D-AMINO ACID-CONTAINING POLYPEPTIDES FOR THERAPEUTIC CONJUGATES AND USES THEREOF | Angiochem Inc. (CA) | 2013-05-08 | — | — | EP | disclosed |
| US-20120141416-A1 | MULTIMERIC PEPTIDE CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2012-06-07 | — | — | US | disclosed |
| WO-2012037687-A9 | THERAPEUTIC POLYPEPTIDES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2012-05-18 | — | — | WO | disclosed |
| EP-2448965-A1 | MULTIMERIC PEPTIDE CONJUGATES AND USES THEREOF | Angiochem Inc. (CA) | 2012-05-09 | — | — | EP | disclosed |
| WO-2012037687-A1 | THERAPEUTIC POLYPEPTIDES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012000118-A1 | SHORT AND D-AMINO ACID-CONTAINING POLYPEPTIDES FOR THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2012-01-05 | — | — | WO | disclosed |
| WO-2011000095-A1 | MULTIMERIC PEPTIDE CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120141416-A1 | MULTIMERIC PEPTIDE CONJUGATES AND USES THEREOF | LNPEP, DNPEP, VIP | MAPK1 3495/4885KMT2A 3839/4885KDM4E 4746/4885 |
| US-20230036041-A1 | SORTILIN BINDING CONJUGATE COMPOUNDS, COMPOSITIONS AND USES THEREOF FOR TREATING CANCER | SORT1, NGLY1, SNX9 | MAPK1 4619/4885KMT2A 3334/4885KDM4E 790/4885 |
| US-20240199695-A1 | PEPTIDE COMPOUNDS AND PEPTIDE CONJUGATES FOR THE TREATMENT OF CANCER THROUGH RECEPTOR-MEDIATED CHEMOTHERAPY | NGLY1, VIP, NPY1R | MAPK1 3794/4885KMT2A 1660/4885KDM4E 314/4885 |
| US-20130280281-A1 | SHORT AND D-AMINO ACID-CONTAINING POLYPEPTIDES FOR THERAPEUTIC CONJUGATES AND USES THEREOF | SLC43A1, SLC7A5, DNPEP | MAPK1 3098/4885KMT2A 2621/4885KDM4E 4312/4885 |
| US-11034727-B2 | Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy | NGLY1, GNRHR, GRPR | MAPK1 3997/4885KMT2A 852/4885KDM4E 98/4885 |
| US-20240156971-A1 | METHODS AND SORTILIN BINDING CONJUGATE COMPOUNDS FOR TARGETING CANCER STEM CELLS | SORT1, CD44, SCARB1 | MAPK1 3801/4885KMT2A 3141/4885KDM4E 4359/4885 |
| US-20220000971-A1 | METHODS AND COMPOUNDS FOR TARGETING SORTILIN RECEPTORS AND INHIBITING VASCULOGENIC MIMICRY | SORT1, FLT1, FLT4 | MAPK1 4148/4885KMT2A 2990/4885KDM4E 555/4885 |
| US-11780882-B2 | Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy | NGLY1, VIP, NPY1R | MAPK1 3786/4885KMT2A 1778/4885KDM4E 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.